How do you use Olpasiran in a sentence? See 2 example sentences showing how this word appears in different contexts.
Olpasiran in a sentence
Context around Olpasiran
- Average sentence length in these examples: 26 words
- Position in the sentence: 0 start, 1 middle, 1 end
- Sentence types: 2 statements, 0 questions, 0 exclamations
Corpus analysis for Olpasiran
- In this selection, "olpasiran" usually appears in the middle of the sentence. The average example has 26 words, and this corpus slice is mostly made up of statements.
- Around the word, future and sales stand out and add context to how "olpasiran" is used.
- Recognizable usage signals include hunt with olpasiran a gene and potential future olpasiran sales. That gives this page its own corpus information beyond isolated example sentences.
- By corpus frequency, "olpasiran" sits close to words such as aabb, aabria and aacha, which helps place it inside the broader word index.
Example types with olpasiran
The same corpus examples are grouped by length and sentence type, making it easier to see the contexts in which the word appears:
Amgen is in the hunt with olpasiran, a gene-silencing drug licensed from Arrowhead Pharmaceuticals that has reached late-stage clinical development. (22 words)
However, with the recent presentation and publication of positive Phase 2 data, we determined that the timing was right to monetize our royalty stream associated with potential future olpasiran sales. (30 words)
However, with the recent presentation and publication of positive Phase 2 data, we determined that the timing was right to monetize our royalty stream associated with potential future olpasiran sales. (30 words)
Amgen is in the hunt with olpasiran, a gene-silencing drug licensed from Arrowhead Pharmaceuticals that has reached late-stage clinical development. (22 words)
Example sentences (2)
Amgen is in the hunt with olpasiran, a gene-silencing drug licensed from Arrowhead Pharmaceuticals that has reached late-stage clinical development.
However, with the recent presentation and publication of positive Phase 2 data, we determined that the timing was right to monetize our royalty stream associated with potential future olpasiran sales.